Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Kromek secures three-year project worth £1.4mln to deliver a molecular breast imaging device

The AIM-listed firm said its CZT-based SPECT detectors will greatly improve the detection of breast cancer in a significant proportion of women
laboratory
Kromek said it has been awarded the funding in partnership with Newcastle-upon-Tyne Hospitals NHS Foundation Trust

Kromek Group PLC (LON:KMK) has been awarded a three-year project by the UK’s innovation agency, Innovate UK to deliver a molecular breast imaging device.

The radiation monitoring company said in a statement that the project, commencing in mid-2018, is worth £1.4mln.

READ: Kromek secured extension of DARPA contract to detect ‘dirty bombs’, worth US$1.6mln

The AIM-listed company added that it has been awarded the funding in partnership with Newcastle-upon-Tyne Hospitals NHS Foundation Trust, to deliver Low Dose Molecular Breast Imaging (LDMBI) technology based on Kromek’s CZT-based SPECT detectors.

By leveraging its SPECT detector technology to develop a functional low dose device, Kromek said it will help unlock the potential for molecular breast imaging, thereby improving detection of cancerous breast tissue in women with denser breast structures.

Kromek said that in the first phase of the project, it will utilise new developments in its SPECT detector technology to reduce the required dose of radiation in molecular breast imaging, a cutting-edge technology, which uses a radioactive tracer to identify tumours.

The LDMBI device will subsequently be used in a pilot study with the Newcastle Hospitals to demonstrate the clinical benefits of incorporating Kromek's SPECT detectors.

Dr Arnab Basu, CEO of Kromek, said: “This project is further evidence that CZT-based detectors are becoming a core technology in replacing legacy diagnostic products across the medical imaging sector.

"Our innovative SPECT detectors are capable of significantly lowering radiation doses, thereby offering cost savings for health services and, crucially, making enhanced detection and early diagnosis of breast cancer accessible on a much wider scale."

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

Jobs market
March 13 2018
A flexible jobs market, an increase in short-term contracts - all play to the strengths of the specialist in background checks
Westminster Group
April 05 2018
Westminster's pipeline of opportunities is strong in the Middle East
Buying online
November 14 2017
The company toned down full-year revenue guidance after a review of procedures but is still growing like topsy

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use